Diagnostics
Two of Merck’s Phase III pediatric trials show 15-valent pneumococcal conjugate vaccine, V114, may be safe and effective in healthy children.
Please check out the biopharma industry’s COVID-19 stories that are trending for May 18, 2021.
PerkinElmer expands its presence with the acquisition of Nexcelom, which would allow the company to expand global efforts to accelerate time to target and time to market for novel therapeutics.
Nearly 50 infants with “bubble baby” disease developed a working immune system after they received a gene therapy that contained the AIDS virus, according to a new study.
Two new venture capital funds, Droia Ventures and Perceptive Advisors closed on new funds to invest in early-stage life science companies.
New mutations of the SARS-CoV-2 virus are continuing to be discovered. As we’ve seen from the most common variants of the virus, infectiousness appears to be the trait most familiar to all of them.
Sepsis is among the best-known and least effectively treated conditions in the modern world. The standard of care has failed for these infections, leaving the U.S. healthcare system with $62 billion and 270,000 deaths annually. Globally, 11 million die from sepsis each year. Effective drugs and diagnostics are available. They’re just not used.
To support the development of immunodiagnostic assay, Sino Biological has successfully generated biologically active and stable Spike and NP proteins of SARS-CoV-2.
EmpowerDX, a Eurofins subsidiary, just launched its direct-to-consumer COVID-19 Home Collection Kit in the U.S. through Amazon, making it one of a miniscule number of at-home and over-the-counter kits that are putting detection of the SARS-CoV-2 virus in the hands of patients.
Shares of GenMark Diagnostics are soaring in premarket trading after Roche announced it was acquiring the California-based company in a $1.8 billion deal to bolster its own diagnostics pipeline.
PRESS RELEASES
